AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic ...

in mCRPC patients previously treated with hormonal therapy and chemo. Merck’s run of bad results is unfortunately par for the course for checkpoint inhibitors in prostate cancer, with other ...

Two weeks after taking an online "liver cancer cure," a 37-year-old man was brought back to hospital in a near-terminal state.

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a debate between Drs. Sia ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...